Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ADC Therapeutics ( (ADCT) ) has issued an announcement.
On October 12, 2025, ADC Therapeutics announced a $60 million private placement with institutional investors, expected to close on October 27, 2025. The proceeds will support the commercial expansion of ZYNLONTA and strengthen the company’s balance sheet, positioning it for long-term growth and a potential relaunch of ZYNLONTA in 2027.
The most recent analyst rating on (ADCT) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.
Spark’s Take on ADCT Stock
According to Spark, TipRanks’ AI Analyst, ADCT is a Neutral.
ADC Therapeutics’ stock score is primarily impacted by its financial instability and ongoing losses, despite strong technical momentum. The negative P/E ratio and lack of dividend yield further weigh on the valuation. While the earnings call provided some positive future growth potential, the restructuring costs and increased net losses are concerning.
To see Spark’s full report on ADCT stock, click here.
More about ADC Therapeutics
ADC Therapeutics is a commercial-stage global leader in the field of antibody drug conjugates (ADCs), focusing on treating hematologic malignancies and solid tumors. The company is advancing its proprietary ADC technology, with its CD19-directed ADC ZYNLONTA receiving accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma.
Average Trading Volume: 827,696
Technical Sentiment Signal: Buy
Current Market Cap: $497.2M
For detailed information about ADCT stock, go to TipRanks’ Stock Analysis page.